Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Piloting a surveillance system for HIV drug resistance in the European Union.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
    • بيانات النشر:
      Publication: Stockholm, Sweden : European Centre for Disease Prevention and Control (ECDC)
      Original Publication: Saint-Maurice : Hôpital national de Saint-Maurice
    • الموضوع:
      Anti-HIV Agents/*pharmacology ; Drug Resistance, Viral/*genetics ; HIV Infections/*drug therapy ; HIV-1/*drug effects; Adult ; Anti-HIV Agents/therapeutic use ; Europe/epidemiology ; European Union ; Feasibility Studies ; Female ; HIV Infections/epidemiology ; HIV Infections/virology ; HIV-1/genetics ; Humans ; Male ; Pilot Projects ; Polymorphism, Genetic ; Population Surveillance ; Prevalence
    • نبذة مختصرة :
      BackgroundA steady increase in HIV drug resistance (HIVDR) has been demonstrated globally in individuals initiating first-line antiretroviral therapy (ART). To support effective use of ART and prevent spread of HIVDR, monitoring is essential.AimWe piloted a surveillance system for transmitted HIVDR to assess the feasibility of implementation at the European level.MethodAll 31 countries in the European Union and European Economic Area were invited to retrospectively submit data on individuals newly diagnosed with HIV in 2015 who were tested for antiviral susceptibility before ART, either as case-based or as aggregate data. We used the Stanford HIV database algorithm to translate genetic sequences into levels of drug resistance.ResultsNine countries participated, with six reporting case-based data on 1,680 individuals and four reporting aggregated data on 1,402 cases. Sequence data were available for 1,417 cases: 14.5% of individuals (n = 244) showed resistance to at least one antiretroviral drug. In case-based surveillance, the highest levels of transmitted HIVDR were observed for non-nucleoside reverse-transcriptase inhibitors (NNRTIs) with resistance detected in 8.6% (n = 145), followed by resistance to nucleoside reverse-transcriptase inhibitors (NRTI) (5.1%; n = 85) and protease inhibitors (2.0%; n = 34).ConclusionWe conclude that standard reporting of HIVDR data was feasible in the participating countries. Legal barriers for data sharing, consensus on definitions and standardisation of interpretation algorithms should be clarified in the process of enhancing European-wide HIV surveillance with drug resistance information.
    • References:
      Clin Infect Dis. 2006 Jun 1;42(11):1608-18. (PMID: 16652319)
      Antivir Ther. 2008;13 Suppl 2:59-68. (PMID: 18575192)
      PLoS One. 2009;4(3):e4724. (PMID: 19266092)
      N Engl J Med. 2011 Aug 11;365(6):493-505. (PMID: 21767103)
      PLoS One. 2012;7(3):e33484. (PMID: 22448246)
      Clin Infect Dis. 2016 Mar 1;62(5):655-663. (PMID: 26620652)
      Infect Genet Evol. 2016 Dec;46:292-307. (PMID: 27587334)
      Euro Surveill. 2017 Jan 12;22(2):. (PMID: 28105988)
      Euro Surveill. 2017 Dec;22(49):null. (PMID: 29233253)
      AIDS. 2018 Apr 24;32(7):877-884. (PMID: 29369826)
    • Contributed Indexing:
      Keywords: HIV/AIDS; pilot study; resistance; surveillance
    • الرقم المعرف:
      0 (Anti-HIV Agents)
    • الموضوع:
      Date Created: 20190516 Date Completed: 20200630 Latest Revision: 20220915
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC6518967
    • الرقم المعرف:
      10.2807/1560-7917.ES.2019.24.19.1800390
    • الرقم المعرف:
      31088600